Catégorie : Substances psychédéliques et therapeutique

Psychedelics and potential benefits in “healthy normals”: A review of the literature, Sam GANDY, 2019

Psychedelics and potential benefits in “healthy normals”: A review of the literature Sam GANDY Journal of Psychedelic Studies, 2019, 3, (3), 280–287. Doi : 10.1556/2054.2019.029   We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of mental health indications still in its early stages, there is an increasing body of research to show that careful use of psychedelics can yield a variety of benefits in “healthy normals” and so lead to “the betterment of well people.” Psychedelics have been found to modulate neuroplasticity, and usage in a supportive setting can result [...]

Lire la suite

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression, Paulo R. Shiroma et al., 2014

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression Paulo R. Shiroma, C. Sophia Albott, Brian Johns, Paul Thuras, Joseph Wels and Kelvin O. Lim The International Journal of Neuropsychopharmacology, 2014, Volume 17, Issue 11, 1805–1813, Doi : 10.1017/S1461145714001011   Abstract The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid anti-depressant effects in treatment-resistant depression (TRD). However, evaluation of ketamine's neurocognitive aspects in TRD has started to be explored. This study aims to (1) examine baseline neurocognitive performance and change in severity of depressive symptoms through six ketamine infusions, (2) examine the neurocognitive effects after completion of serial infusions and whether changes were associated to [...]

Lire la suite

A phenomenology of subjectively relevant experiences induced by ayahuasca in Upper Amazon vegetalismo tourism, Tom John Wolff et al., 2018

A phenomenology of subjectively relevant experiences induced by ayahuasca in Upper Amazon vegetalismo tourism Tom John Wolff, Simon Ruffell, Nigel Netzband and Torsten Passie Journal of Psychedelic Studies, 2018 Doi : 10.1556/2054.2019.007   Aims : This heuristic study reports observations on the phenomenology of ayahuasca experiences of nine foreign tourist participants of an ayahuasca retreat in Peru. Methods : Narrative interviews, reflecting individual experiences after ayahuasca “night ceremony,” have been analyzed by qualitative content analysis using a data-driven strategy in order to extract themes and categories inherent in the interviews. Previously, a demographic questionnaire was given. The dose–response connection was uncontrolled, which is typical for this [...]

Lire la suite

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial, Steliana Yanakieva et al., 2018

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial Steliana Yanakieva, Naya Polychroni, Neiloufar Family, Luke T. J. Williams, David P. Luke, Devin B. Terhune Psychopharmacology, 2018 Doi : 10.1007/s00213-018-5119-x   Abstract Rationale : Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neurochemical effects on interval timing from indirect effects attributable to altered states of consciousness. Methods : We conducted a randomised, double-blind, [...]

Lire la suite

A systematic study of microdosing psychedelics, Vince Polito & Richard J. Stevenson, 2019

A systematic study of microdosing psychedelics RESEARCH ARTICLE Vince Polito, Richard J. Stevenson PLoS ONE, 2019, 14, (2), e0211023. Doi : 10.1371/journal.pone.0211023   Abstract The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popularity in recent years. Individuals who microdose report minimal acute effects from these substances yet claim a range of long-term general health and wellbeing benefits. There have been no published empirical studies of microdosing and the current legal and bureaucratic climate makes direct empirical investigation of the effects of psychedelics difficult. In Study One we conducted a systematic, observational investigation of individuals [...]

Lire la suite

Accounting for Microdosing Classic Psychedelics, Blake Beaton et al., 2019

Accounting for Microdosing Classic Psychedelics Blake Beaton, Heith Copes, Megan Webb, Andy Hochstetler, and Peter S. Hendricks Journal of Drug Issues, 2019, 1–12 Doi : 10.1177/0022042619871008   Abstract Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substances to bring about various positive life changes. Little is known about the subjective experiences and perceptions of those who engage in the practice. Accordingly, we use the sociology of accounts as a theoretical framework to explore the ways that those who microdose excuse or justify their practice. Using data from semistructured interviews with 30 people who had microdosed, [...]

Lire la suite

A propos de : Voyage aux confins de l’esprit, de Michael Pollan, Dopamine, 13, 2020

A propos de : Voyage aux confins de l’esprit, de Michael Pollan (Ce que le LSD et la psilocybine nous apprennent sur nous-mêmes, la conscience, la mort, les addictions et la dépression) à propos de l'ouvrage de Michael Pollan Traduction : Leslie Talaga et Caroline Lee Editions Quanto, octobre 2019 444 pages - 23,25 euros Dans l'excellente Revue Dopamine, 2020, n°13, pp 59-69 Ce voyage aux confins de l’esprit de Michael Pollan, journaliste scientifique, nous embarque sur la planète psychédélique, celle où des substances comme le LSD ou les champignons psilocybes, par exemple, ont acquis du galon... Après avoir eu leurs heures de gloire dans les années [...]

Lire la suite

Comment microdoser du LSD m’aide à gérer mon autisme, Charlie Ellis, Vice, 08 Janvier 2020

Comment microdoser du LSD m'aide à gérer mon autisme Charlie Ellis Vice, 08 Janvier 2020 https://www.vice.com/fr/article/4agd7d/comment-microdoser-du-lsd-maide-a-gerer-mon-autisme "Je prends fréquemment de très petites quantités de psychédélique pour combler le fossé avec les personnes neurotypiques." C’est toujours le même rituel. J’aime les rituels, ils rationalisent l’absurdité de nos existences et me permettent de continuer à vivre. Réveil engourdi, lavage de mains compulsif, 20 grammes de café et 15 microgrammes de LSD sous la langue. Je suis prête à affronter le monde neurotypique – le monde de ceux qui ne sont pas autistes. Je suis autiste. Je pense, ressens et traite les informations de manière complètement différente. J’ai [...]

Lire la suite

A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens, Ümit Sayin, 2012

A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens Ümit Sayin NeuroQuantology, June 2012, Volume 10, Issue 2,  316-340. eISSN 1303-5150   ABSTRACT Altered states of consciousness induced by hallucinogens (H-ASC) is still a vaguely understood phenomenon. Taken the diverse psychological effects they exert, the main mechanism of action of hallucinogens; LSD, ibogaine, THC, PCP, MDMA, methamphetamine, mescaline, psilocybin and DMT, of which psychological effects are discussed in the article, are not properly understood and explained by the modern methods of neuroscience due to the lack of vigorous research. The involvement of some receptors, such as, [...]

Lire la suite

Psilocybin Benefits in Cancer Sustained Nearly 5 Years Later, Nancy A. Melville, 2020

Psilocybin Benefits in Cancer Sustained Nearly 5 Years Later Nancy A. Melville Medscape, January 28, 2020 Medscape Medical News © 2020 Cancer patients who were treated with a one-time, single dose of the psychedelic drug psilocybin, combined with psychotherapy, showed significant benefits on measures of emotional and existential distress nearly 5 years after receiving the therapy, new research indicates. In addition to reporting improved well-being or life satisfaction, some patients rated the treatment as being "among the most personally meaningful and spiritually significant experiences of their lives," the authors note. The study, the longest-spanning evaluation to date of the effects of psilocybin in the treatment of cancer-related psychiatric distress, was [...]

Lire la suite